Kingston Yeung, Gi Kon Nam, Klaudia Englezos, Aagam Bordia, Stephen Carter, Rebekah Moles, Hana Amer, Manya Angley, Charley Budgeon, Brett Chambers, Jenny Chen, Deirdre Criddle, Rohan A Elliott, Tara Emadi, Cristen Fleming, Deborah Hawthorne, Linda Krogh, Anna Packer, Simon Poon, Frank M Sanfilippo, Paul Yates, Jerry Yik, Jonathan Penm
{"title":"Proportion of patients admitted to rural and remote hospitals that experience a 30-day medication-related readmission: a retrospective cohort study.","authors":"Kingston Yeung, Gi Kon Nam, Klaudia Englezos, Aagam Bordia, Stephen Carter, Rebekah Moles, Hana Amer, Manya Angley, Charley Budgeon, Brett Chambers, Jenny Chen, Deirdre Criddle, Rohan A Elliott, Tara Emadi, Cristen Fleming, Deborah Hawthorne, Linda Krogh, Anna Packer, Simon Poon, Frank M Sanfilippo, Paul Yates, Jerry Yik, Jonathan Penm","doi":"10.1007/s11096-026-02228-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Medication-related readmissions are a significant and preventable cause of patient harm. Patients living in rural and remote areas may face inequitable access to healthcare and fragmented continuity of care, increasing their vulnerability to medication-related harm. Despite this, the burden and drivers of medication-related readmissions in these settings remain poorly understood. Determining the current burden and identifying factors associated with medication-related readmissions is essential to inform targeted strategies to improve medication safety.</p><p><strong>Aim: </strong>To determine the proportion of adult patients with a medication-related readmission within 30 days of discharge from rural and remote hospitals, and to identify factors potentially associated with these readmissions.</p><p><strong>Method: </strong>A retrospective cohort study was conducted using medical records of adults admitted to rural and remote hospitals in New South Wales, Australia, between June 1, 2022 and August 31, 2023. Readmissions within 30 days were assessed for medication-related causes using the AT-HARM10, a validated 10-item tool based on admission notes, medication lists, inpatient pathology results, and discharge summaries. Patient demographics, comorbidities and admission details were extracted. Comorbidity burden was calculated using the Charlson Comorbidity Index (CCI). Medication lists were based on medications charted 12 h before discharge. Univariable logistic regression was performed to explore factors associated with 30-day medication-related readmissions, with results reported as unadjusted odds ratios (uOR).</p><p><strong>Results: </strong>Of the 2220 patients admitted during the study period, 6% (n = 133) experienced a 30-day readmission, of which 22.5% (n = 30) were medication-related. Overall, 1.4% of all admitted patients experienced a 30-day medication-related readmission. Older age (uOR 1.04; 95% CI 1.01-1.07), higher CCI (uOR 1.22; 95% CI 1.04-1.44), a greater number of regular medications (uOR 1.07 per additional medication; 95% CI 1.01-1.14), and insulin use (uOR 2.80; 95% CI 1.06-7.42) were associated with medication-related readmission.</p><p><strong>Conclusion: </strong>In rural and remote hospitals, a small but clinically important proportion of patients experienced a medication-related readmission within 30 days of discharge. Unadjusted analysis identified that older age, multimorbidity, polypharmacy and insulin use were associated with increased risk. Larger studies are needed to validate these findings and evaluate strategies to reduce medication-related harm in rural and remote populations.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11096-026-02228-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Medication-related readmissions are a significant and preventable cause of patient harm. Patients living in rural and remote areas may face inequitable access to healthcare and fragmented continuity of care, increasing their vulnerability to medication-related harm. Despite this, the burden and drivers of medication-related readmissions in these settings remain poorly understood. Determining the current burden and identifying factors associated with medication-related readmissions is essential to inform targeted strategies to improve medication safety.
Aim: To determine the proportion of adult patients with a medication-related readmission within 30 days of discharge from rural and remote hospitals, and to identify factors potentially associated with these readmissions.
Method: A retrospective cohort study was conducted using medical records of adults admitted to rural and remote hospitals in New South Wales, Australia, between June 1, 2022 and August 31, 2023. Readmissions within 30 days were assessed for medication-related causes using the AT-HARM10, a validated 10-item tool based on admission notes, medication lists, inpatient pathology results, and discharge summaries. Patient demographics, comorbidities and admission details were extracted. Comorbidity burden was calculated using the Charlson Comorbidity Index (CCI). Medication lists were based on medications charted 12 h before discharge. Univariable logistic regression was performed to explore factors associated with 30-day medication-related readmissions, with results reported as unadjusted odds ratios (uOR).
Results: Of the 2220 patients admitted during the study period, 6% (n = 133) experienced a 30-day readmission, of which 22.5% (n = 30) were medication-related. Overall, 1.4% of all admitted patients experienced a 30-day medication-related readmission. Older age (uOR 1.04; 95% CI 1.01-1.07), higher CCI (uOR 1.22; 95% CI 1.04-1.44), a greater number of regular medications (uOR 1.07 per additional medication; 95% CI 1.01-1.14), and insulin use (uOR 2.80; 95% CI 1.06-7.42) were associated with medication-related readmission.
Conclusion: In rural and remote hospitals, a small but clinically important proportion of patients experienced a medication-related readmission within 30 days of discharge. Unadjusted analysis identified that older age, multimorbidity, polypharmacy and insulin use were associated with increased risk. Larger studies are needed to validate these findings and evaluate strategies to reduce medication-related harm in rural and remote populations.
药物相关再入院是患者伤害的重要和可预防的原因。生活在农村和偏远地区的患者可能面临获得医疗保健的不公平机会和断断续续的护理连续性,从而增加了他们遭受药物相关伤害的脆弱性。尽管如此,在这些环境中,与药物有关的再入院的负担和驱动因素仍然知之甚少。确定目前的负担和确定与药物相关的再入院相关的因素对于制定有针对性的战略以提高药物安全性至关重要。目的:确定农村和偏远医院出院后30天内与药物相关再入院的成年患者比例,并确定与这些再入院相关的潜在因素。方法:对2022年6月1日至2023年8月31日期间在澳大利亚新南威尔士州农村和偏远医院住院的成年人的医疗记录进行回顾性队列研究。使用AT-HARM10评估30天内再入院的药物相关原因,AT-HARM10是一个经过验证的10项工具,基于入院记录、药物清单、住院病理结果和出院摘要。提取患者统计资料、合并症和入院细节。采用Charlson共病指数(CCI)计算共病负担。用药清单根据出院前12小时的药物图表。采用单变量logistic回归探讨与30天药物相关再入院相关的因素,结果报告为未调整的优势比(uOR)。结果:在研究期间入院的2220例患者中,6% (n = 133)经历了30天的再入院,其中22.5% (n = 30)与药物有关。总体而言,1.4%的入院患者经历了30天的药物相关再入院。年龄较大(危险度1.04;95% CI 1.01-1.07)、较高的CCI(危险度1.22;95% CI 1.04-1.44)、较多的常规用药(每额外用药危险度1.07;95% CI 1.01-1.14)和胰岛素使用(危险度2.80;95% CI 1.06-7.42)与药物相关再入院相关。结论:在农村和偏远医院,一小部分患者在出院后30天内再次出现与药物相关的再入院,这一比例具有重要的临床意义。未经调整的分析发现,年龄较大、多病、多种药物和胰岛素使用与风险增加有关。需要更大规模的研究来验证这些发现,并评估减少农村和偏远人口药物相关危害的策略。
期刊介绍:
The International Journal of Clinical Pharmacy (IJCP) offers a platform for articles on research in Clinical Pharmacy, Pharmaceutical Care and related practice-oriented subjects in the pharmaceutical sciences.
IJCP is a bi-monthly, international, peer-reviewed journal that publishes original research data, new ideas and discussions on pharmacotherapy and outcome research, clinical pharmacy, pharmacoepidemiology, pharmacoeconomics, the clinical use of medicines, medical devices and laboratory tests, information on medicines and medical devices information, pharmacy services research, medication management, other clinical aspects of pharmacy.
IJCP publishes original Research articles, Review articles , Short research reports, Commentaries, book reviews, and Letters to the Editor.
International Journal of Clinical Pharmacy is affiliated with the European Society of Clinical Pharmacy (ESCP). ESCP promotes practice and research in Clinical Pharmacy, especially in Europe. The general aim of the society is to advance education, practice and research in Clinical Pharmacy .
Until 2010 the journal was called Pharmacy World & Science.